创新药概念活跃，睿智医药20%涨停，药明康德等走高

Core Insights - The innovative drug sector experienced a strong rally on December 9, with notable stock performances including a 20% limit up for Ruizhi Pharmaceutical and approximately 13% increases for Chengda Pharmaceutical and Boji Pharmaceutical [1] - The final agreement text of the National Defense Authorization Act (NDAA) for fiscal year 2025 was released by the U.S. Congress on December 7, 2024, which did not include the biosafety bill [1] - The absence of the biosafety bill in the NDAA is viewed positively for WuXi AppTec and other Chinese CRO/CDMO companies with significant overseas revenue exposure [1]